AprilBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
AprilBio develops antibody-based medicines and long-acting protein drugs, biological therapies designed to treat autoimmune, inflammatory, cancer, and rare diseases.
It is a research-stage biotech listed on KOSDAQ, Korea's tech-focused stock exchange, that advances drug candidates through early clinical stages and then licenses them to larger pharmaceutical partners worldwide. Its core business model, which it calls RIPCO, is to earn revenue through upfront payments, milestone fees, and royalties from these technology-licensing deals rather than commercializing drugs itself.
Summary is AI-generated and may contain errors · figures from DART filings
AprilBio was founded as a faculty-led spin-out from academia, a common origin for Korean biotech companies, and its pipeline is built around two proprietary platform technologies it developed in-house.
AprilBio in five facts
What does AprilBio do?
AprilBio develops antibody-based medicines and long-acting protein drugs, biological therapies designed to treat autoimmune, inflammatory, cancer, and rare diseases.
Where is AprilBio listed and in which sector?
AprilBio (Korean name: 에이프릴바이오) trades under KRX code 397030 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is AprilBio?
Its market capitalisation was US$280.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were AprilBio's latest annual revenue and operating profit?
For fiscal year 2025, AprilBio reported revenue of US$1.6M, an operating loss of US$5.5M and a net loss of US$7.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 92.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 7
- Report on large shareholdings (5% rule) (standard)Sep 28
- Results of extraordinary shareholders' meetingSep 22
- Grant of stock optionsSep 22
- Appointment/dismissal/resignation of an independent directorSep 22
- Report on securities held by executives/major shareholdersSep 18
- Report on securities held by executives/major shareholdersSep 17
- Report on large shareholdings (5% rule) (abbreviated)Sep 9
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 7
- Notice of general shareholders' meetingSep 7
- [Amended] Change of largest shareholder
AprilBio amends its July 24, 2026 change-of-largest-shareholder disclosure to add that on August 19, 2026 Shinhan Investment Corp. assigned part of its loan to IMM Scale-up Bio No. 1 LLC (US$10.8M to IBK Capital Corporation and US$3.6M to SBI Savings Bank), changing the pledge holders over the 708,000 collateral shares; the underlying change had made IMM Healthcare No. 8 LLC and 2 others (19.22%, 5,981,862 shares) the new largest shareholder in place of Cha Sang-hoon and 2 others (19.39%, 4,541,000 shares).
Ownership change · Aug 19 · 2 versions - Share-pledge agreement that may change the largest shareholder
AprilBio's largest shareholder (IMM Healthcare No. 8 Ltd.) pledged shares as loan collateral to a company, securing up to US$39.1M.
Ownership change · Jul 24 - Securities issuance results (voluntary)
AprilBio completed a third-party-placement rights offering of 3,608,595 voting convertible preferred shares for US$105M, paid in on 2026-07-23; the new shares will not be listed and will be held in escrow with the Korea Securities Depository for one year.
Capital raise · Jul 23 - [Amended] Agreement on change of control signed
AprilBio's controlling stake is now set to change hands, in a deal worth US$102M.
Ownership change · Jul 23 · 2 versions - [Amended] Material event report (rights offering)
AprilBio updated the terms of convertible bonds to raise US$33.9M, about 11.3% of its market value.
Capital raise · Jul 23 - [Amended] Material event report (rights offering)
AprilBio updated the terms of a private placement (third-party allotment) to raise US$96.2M, about 32.0% of its market value.
Capital raise · Jul 23 - [Amended] Agreement on change of control signed
AprilBio's controlling stake is now set to change hands, in a deal worth US$97M.
Ownership change · Jun 25 - Material event report (rights offering)
AprilBio disclosed convertible bonds to raise US$32.3M, about 11.3% of its market value.
Capital raise · Jun 25 - Material event report (rights offering)
AprilBio disclosed convertible bonds to raise US$100M, about 35.0% of its market value.
Capital raise · Jun 25 - Material event report (rights offering)
AprilBio disclosed a private placement (third-party allotment) to raise US$91.7M, about 32.0% of its market value.
Capital raise · Jun 25 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
AprilBio reported separate results for FY2025: revenue of US$1.49M (−92.11% year on year), an operating loss of US$4.97M (from a profit a year earlier) and a net loss of US$6.65M (from a profit a year earlier).
Earnings · Feb 9